Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: A phase II study

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 387-392

  Martoni, A A ^a   Melotti, B ^a   Sperandi, F ^a   Giaquinta, S ^a   Piana, E ^a   Pavesi, L ^b   Da Prada, G ^b   Lelli, G ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cis platin dose; Consolidation treatment; First line chemotherapy; NSCLC; Oral chemotherapy; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RARE DISEASE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; TREATMENT PLANNING; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 44449160004     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.006     Document Type: Article

References (18)

1. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
2. Depierre A., Chastang C.L., Quoix E., Lebeau B., Blanchon F., Paillot N., et al. Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann Oncol 5 (1994) 37-42
3. Crawford J., O'Rourke M., Schiller J.H., Spiridonidis C.H., Yanovich S., Ozer H., et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV NSCLC. J Clin Oncol 14 (1996) 2774-2784
4. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
5. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 2459-2465
6. Martoni A., Marino A., Sperandi F., Giaquinta S., Di Fabio F., Melotti B., et al. Multicentre randomized phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41 (2005) 81-92
7. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12 (2001) 1643-1649
8. Lush R.M., McCune J.S., Tetteh L., Thompson J.A., Mahany J.J., Garland L., et al. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 56 (2005) 578-584
9. Jassem J., Ramlau R., Karnicka-Mfodkowska H., Krawczyk K., Krzakowski M., Zatloukal P., et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12 (2001) 1375-1381
10. De Lena M.D., Ramlau R., Hansen O., Lorusso V., Wagner L., Barni S., et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 48 (2005) 129-135
11. Green S., and Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10 (1992) 239-253
12. National cancer Institute. Common Toxicity Criteria (CTC), version 3.0. http://ctep.cancer.gov/reporting/ctc.htlm.
13. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 21 (2003) 3016-3024
14. Jassem J., Kosmidis P., Ramlau R., Zarogoulidis K., Novakova L., Breton J., et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14 (2003) 1634-1639
15. Chen Y.M., Yu C.J., Yang C.H., Perng R.P., Tsai C.M., Shih J.F., et al. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 56 (2007) 89-95
16. O'Brien M.E., Szczesna A., Karnicka H., Zatloukal P., Eisen T., Hartmann W., et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 15 (2004) 921-927
17. Grossi F., Aita M., Follador A., Defferrari C., Brianti A., Sinaccio G., and Belvedere O. Sequential, alternative, and maintainance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. The Oncologist 12 (2007) 451-464
18. French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 499-506